Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Clinical trials with anti-angiogenic agents in hematological malignancies
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 3591659
Author(s) Medinger, Michael; Mross, Klaus
Author(s) at UniBasel Medinger, Michael
Year 2010
Title Clinical trials with anti-angiogenic agents in hematological malignancies
Journal Journal of Angiogenesis Research
Volume 2
Number 1
Pages / Article-Number 10
Abstract New blood vessel formation (angiogenesis) is not only essential for the growth of solid tumors but there is also emerging evidence that progression of hematological malignancies like multiple myeloma, acute leukemias, and myeloproliferative neoplasms, also depends on new blood vessel formation. Anti-angiogenic strategies have become an important therapeutic modality for solid tumors. Several anti-angiogenic agents targeting angiogenesis-related pathways like monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulatory drugs, and proteasome inhibitors have been entered clinical trials or have been already approved for the treatment of hematological malignancies as well and in some instances these pathways have emerged as promising therapeutic targets. This review summarizes recent advances in the basic understanding of the role of angiogenesis in hematological malignancies and clinical trials with novel therapeutic approaches targeting angiogenesis.
Publisher BioMed Central
ISSN/ISBN 2040-2384
edoc-URL http://edoc.unibas.ch/43923/
Full Text on edoc No
Digital Object Identifier DOI 10.1186/2040-2384-2-10
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/20569499
ISI-Number MEDLINE:20569499
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.355 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
02/05/2024